PHARMACY

Allergan, Adamas announce new Namzaric dosage strengths availability

BY David Salazar
DUBLIN and EMERYVILLE, Calif. —Allergan and Adamas Pharmaceuticals on Thursday announced the availability of all four dosage strengths of its Namzaric (memantine and donepezil hydrochloride) extended-release capsules. 
 
Namzaric is a fixed-dose combination of memantine and 10 mg donepezil hydrochloride indicated to treat moderate to severe Alzheimer’s disease in patients stabilized on 10 mg of donepezil hydrochloride. The Food and Drug Administration approved the drug in July. 
 
“We are excited that with the new available dosage strengths patients with moderate to severe Alzheimer's disease, who are currently stabilized on Aricept, donepezil hydrochloride (10 mg) can now start combination therapy directly with NAMZARIC,” Allergan chief medical officer Dr. Gavin Corcoran said. Namzaric offers these patients the benefits of combining two products that each work differently to treat moderate to severe Alzheimer's disease, without increasing the number of pills a patient and their caregiver need to administer each day.”
 
Namzaric will be commercially available in 30-count bottles of 7-, 10-, 14-, 21- and 28-mg memantine/10-mg donepezil hydrochloride dosage strengths. 
 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Report: Opioid abuse cost burden exceeds $78 billion

BY DSN STAFF
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

PhRMA brings scientists to Capitol Hill

BY David Salazar
WASHINGTON — The Pharmaceutical Research and Manufacturers of America (PhRMA) on Wednesday brought 60 of its member companies’ researchers to Capitol Hill for meetings with members of Congress. The researchers will discuss with lawmakers how they can support developing new, innovative medicines. 
 
“America's biopharmaceutical researchers and scientists are on the frontlines of cutting-edge science bringing new treatments and cures to patients,” PhRMA president and CEO Stephen J. Ubl said. “I'm excited that our companies will be visiting with members of Congress to share why it's critical to support pro-innovation policies that continue to allow America to be the leader in biopharmaceutical innovation around the globe.”
 
PhRMA said researchers will also discuss the strides made in recent years by the biopharmaceutical industry, among them innovative hepatitis C medicines and more than 500 medicines developed to treat rare diseases that affect 25 million Americans. 
 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?